Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OptumRx Inc.
In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.
From illegal importation under FDCA to possible ERISA, HIPAA and ACA violations – a task force led by CancerCare is pushing regulatory agencies with levers to go after employer plans use of alternative funding programs for specialty drugs, which they say violate multiple federal laws.
New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.
There are many new pressures on biopharmaceutical profitability but will Merck & Co’s attempt to reverse the drug pricing aspects of the Inflation Reduction Act just divert costs to patients?
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.